Condition Focus: Osteoarthritis — Complete Inflammatory Mediator Panel
This 2017 study from Tomazoni and colleagues is notable for measuring PBM’s effects on the complete panel of inflammatory mediators that drive joint disease — IL-1β, IL-6, TNF-α, and PGE₂ — all within a single controlled experiment using a rat osteoarthritis model.
The results showed that PBM reduced all four mediators at the protein expression level. This is not a review summarising scattered findings across multiple studies; it is a single experiment demonstrating comprehensive cytokine suppression in an inflammatory joint.
For gout, these four mediators are not just relevant — they are the disease itself. IL-1β is the primary output of NLRP3 inflammasome activation by urate crystals and the central driver of the acute flare. TNF-α amplifies the inflammatory signal and recruits neutrophils. IL-6 drives systemic inflammatory responses and contributes to joint damage. PGE₂ is the prostaglandin responsible for pain sensitisation — the same molecule that NSAIDs are designed to suppress via COX inhibition.
The fact that PBM suppresses all four simultaneously, through a non-pharmacological mechanism, positions it as a multi-target intervention that achieves what no single drug can: comprehensive inflammatory mediator suppression without blocking any one pathway to the point of immune compromise or organ toxicity.
G.O.A.T. for Gout Alignment:
The G.O.A.T.’s dual-wavelength output targets the mitochondrial and cellular pathways upstream of all four mediators measured here. Rather than blocking PGE₂ alone (NSAIDs) or IL-1β alone (colchicine/biologics), the G.O.A.T.’s PBM approach modulates the cellular environment that produces the entire inflammatory panel.
Link to original research here
Editor’s note: The PGE₂ suppression shown here is explored mechanistically through the COX-2 pathway in Albertini et al 2007. The IL-1β reduction connects directly to the NLRP3 inflammasome outputs measured in Shamloo et al 2023. For the meta-analytic confirmation of these biomarker effects across multiple OA studies, see Nambi 2021. The neutrophil infiltration that IL-6 and TNF-α drive in joints is examined in Alves et al 2014.
Related Articles
- Anti-Inflammatory Effect of PBM on COX-2 and PGE₂ in Joint Inflammation – Albertini et al 2007
- PBM Suppresses NLRP3 Outputs with Dual Wavelength – Shamloo et al 2023
- LLLT Effects on Inflammatory Biomarkers in OA: Meta-Analysis – Nambi 2021
- Effect of PBM on Inflammatory Mediators and Neutrophils in Joint Inflammation – Alves et al 2014
- PBM Ameliorates Inflammatory Parameters in Fibroblast-Like Synoviocytes – Ryu et al 2023
Key Takeaways
- PBM reduced all four key inflammatory mediators (IL-1β, IL-6, TNF-α, PGE₂) in a single joint model
- These four mediators are the exact drivers of acute gout flares via the NLRP3 inflammasome cascade
- PGE₂ is the NSAID target — PBM achieves the same suppression without COX inhibition
- Multi-target suppression without single-pathway immune compromise or organ toxicity
Study Overview
| Study Type: | Controlled animal study (preclinical) |
| Wavelength(s): | PBMT protocol (specific wavelength not reported in abstract) |
| Treatment Protocol: | Defined treatment course in experimental OA model |
| Sample Size: | Multiple rat groups (OA model, untreated, pharmacological, exercise controls) |
| Primary Outcome: | Reduction of IL-1β, IL-6, TNF-α, and PGE₂ at protein expression level |
Full Citation
Tomazoni SS, Leal-Junior ECP, Pallotta RC, et al. (2017). Effects of photobiomodulation therapy on inflammatory response in experimental osteoarthritis. Lasers in Medical Science, 32(5), 1153–1160. View Publication
